LifeSciences BC > News > Member Announcements

Quark Venture Inc. and GF Securities Participate in Keros Therapeutics’ $23 million Series B Financing for Development of Therapies to Treat Debilitating Neuromuscular Diseases

January 7, 2019
Quark Venture Inc.

Vancouver, BC – January 7, 2018 – Quark Venture Inc. (Quark) and GF Securities are pleased to announce their investment in Keros Therapeutics, a company dedicated to the discovery and development of novel therapeutics for neuromuscular diseases. The investment, made through their Global Health Sciences Fund (GHS) is part of the $23 million Series B … Continue reading Quark Venture Inc. and GF Securities Participate in Keros Therapeutics’ $23 million Series B Financing for Development of Therapies to Treat Debilitating Neuromuscular Diseases

Xenon Pharmaceuticals Outlines 2019 Key Milestones

January 7, 2019
Xenon Pharmaceuticals Inc.

Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 BURNABY, British Columbia, Jan. 06, 2019 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided a corporate update and outlined its anticipated key milestone events in 2019. Dr. Simon Pimstone, Xenon’s … Continue reading Xenon Pharmaceuticals Outlines 2019 Key Milestones

Phyton Biotech Partners with Agenus to Revolutionize QS-21 Production

January 3, 2019

Agenus’ R&D Project Funded by Bill & Melinda Gates Foundation Employs PCF® Technology for Potent Vaccine Ingredient FORT WORTH, Texas, January 3, 2019 – Phyton Biotech today announced an exclusive partnership with Agenus Inc. to develop an alternative manufacturing process for QS-21 to ensure a sustainable supply of this key vaccine ingredient. Agenus received a … Continue reading Phyton Biotech Partners with Agenus to Revolutionize QS-21 Production

Canada’s Digital Technology Supercluster officially launches with $153M in funding from the Ministry of Innovation, Science and Economic Development and funding commitments of over $200M from members

December 5, 2018
Canada’s Digital Technology Supercluster

Vancouver – November 27, 2018 – Canada’s Digital Technology Supercluster is excited to announce its official launch and celebrate the funding allocation by the Ministry of Innovation, Science, and Economic Development (ISED) and funding commitments by its initial cohort of members. The Government of Canada is investing up to $950 million over five years to … Continue reading Canada’s Digital Technology Supercluster officially launches with $153M in funding from the Ministry of Innovation, Science and Economic Development and funding commitments of over $200M from members

Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting

December 3, 2018
Xenon Pharmaceuticals Inc.

XEN1101 CTA Accepted by Health Canada for Initiation of Phase 2 Clinical Trial in Adult Focal Epilepsy; U.S. IND Filing Targeted in Q1 2019 Conference Call to Discuss Xenon’s Epilepsy Programs at 9 am ET Today BURNABY, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today … Continue reading Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting

Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting

November 30, 2018
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Nov. 30, 2018 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, December 3, 2018 at 9:00 am Eastern Time (6:00 am Pacific Time) to provide a corporate update and overview of the Company’s poster … Continue reading Xenon Pharmaceuticals to Host Conference Call and Webcast to Provide Corporate Update and Overview of Presentations at the 2018 American Epilepsy Society (AES) Meeting

INSTI HIV Self Test Earns WHO Prequalification Status for Home Testing

November 28, 2018
bioLytical Laboratories Inc.

The newly WHO Prequalified INSTI HIV Self Test makes a mark as it expands into new markets VANCOUVER, BC, November 28, 2018 /CNW/ – bioLytical Laboratories, a world leader in rapid infectious disease tests, is pleased to announce that its INSTI® HIV Self Test has been Prequalified  by the World Health Organization (WHO).  INSTI, the world’s fastest home … Continue reading INSTI HIV Self Test Earns WHO Prequalification Status for Home Testing

Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors

November 27, 2018
Arbutus Biopharma Corporation

WARMINSTER, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Frank Torti has been appointed as Chairman of the Company’s Board of Directors, effective November 26, 2018. “We are pleased to welcome Frank to our Board,” said Dr. Mark J Murray, President and CEO of Arbutus. … Continue reading Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors

DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting

November 20, 2018
DelMar Pharmaceuticals, Inc.

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 20, 2018 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, presented scientific updates, including data from two ongoing clinical trials, at the 23rd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) … Continue reading DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting

ASPECT BIOSYSTEMS RECEIVES $2.7M INVESTMENT FROM THE GOVERNMENT OF CANADA

November 15, 2018

Government of Canada invests nearly $20M in top British Columbia companies in 2018 VANCOUVER, British Columbia – November 15, 2018 – Aspect Biosystems, a leader in the field of 3D bioprinting and tissue engineering, has received $2.7 million from the Government of Canada’s Western Innovation (WINN) Initiative. WINN has funded 17 projects in British Columbia … Continue reading ASPECT BIOSYSTEMS RECEIVES $2.7M INVESTMENT FROM THE GOVERNMENT OF CANADA